Skip to main content
Erschienen in: International Journal of Colorectal Disease 4/2004

01.07.2004 | Original Article

Prognostic value of disseminated colorectal tumor cells in the liver: results of follow-up examinations

verfasst von: Ulrich Linnemann, Christoph C. Schimanski, Christoph Gebhardt, Martin R. Berger

Erschienen in: International Journal of Colorectal Disease | Ausgabe 4/2004

Einloggen, um Zugang zu erhalten

Abstract

Background and aims

Dissemination of tumor cells is an initial step in metastatic disease. Detection of disseminated tumor cells (DTC) in blood, bone marrow and lymph nodes has been associated with reduced disease-free survival, but to date there are no data for hepatic DTC. We investigated the prognostic relevance of hepatic DTC that are present in patients with colorectal cancer (CRC) at the time of surgery.

Patients and methods

In 121 patients with CRC clinically diagnosed for liver metastasis by ultrasound, CT, and exploration during surgery DNA from liver biopsy specimens obtained during surgery was examined by a PCR-RFLP assay for K-ras mutations as a marker for DTC. At the time of surgery 54 of the 121 were mutated in K-ras codons 12 or 13. After a median follow-up of 405 days all survivors were reevaluated by ultrasound/CT.

Results

Patients with a K-ras mutation in their primary tumor had a significantly lower probability of survival and higher risk of harboring a synchronous second colorectal carcinoma than patients with a K-ras wild-type tumor. Based on specimens taken intraoperatively DTC were found in the liver of 14 of 54 patients (26%). At follow-up only 10 of 40 patients (25%) with DTC-free liver had died of their disease but 9 of the 14 patients with hepatic DTC. Among the 14 patients with hepatic DTC 10 (71%) had developed new liver metastasis, compared to 12 of 40 (30%) in those without hepatic DTC.

Conclusion

Hepatic DTC in colorectal cancer patients is associated with reduced overall survival and increased risk of hepatic metastasis development. Further studies are necessary to corroborate our results since the number of patients studied is still limited.
Literatur
1.
Zurück zum Zitat August DA, Ottow RT, Sugarbaker PH (1984) Clinical perspective of human colorectal cancer metastasis. Cancer Metastasis Rev 3:303–324PubMed August DA, Ottow RT, Sugarbaker PH (1984) Clinical perspective of human colorectal cancer metastasis. Cancer Metastasis Rev 3:303–324PubMed
2.
Zurück zum Zitat Deans GT, Parks TG, Rowlands BJ, Spence RA (1992) Prognostic factors in colorectal cancer. Br J Surg 79:608–613PubMed Deans GT, Parks TG, Rowlands BJ, Spence RA (1992) Prognostic factors in colorectal cancer. Br J Surg 79:608–613PubMed
3.
Zurück zum Zitat Weiss L, Grundmann E, Torhorst J, Hartveit F, Moberg I, Eder M, Fenoglio-Preiser CM, Napier J, Horne CH, Lopez MJ (1986) Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol 150:195–203PubMed Weiss L, Grundmann E, Torhorst J, Hartveit F, Moberg I, Eder M, Fenoglio-Preiser CM, Napier J, Horne CH, Lopez MJ (1986) Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol 150:195–203PubMed
4.
Zurück zum Zitat Gilbert JM (1983) Distribution of metastases at necropsy in colorectal cancer. Clin Exp Metastasis 1:97–101PubMed Gilbert JM (1983) Distribution of metastases at necropsy in colorectal cancer. Clin Exp Metastasis 1:97–101PubMed
5.
Zurück zum Zitat Sanchez-Cespedes M, Esteller M, Hibi K, Cope FO, Westra WH, Piantadosi S, Herman JG, Jen J, Sidransky D (1999) Molecular detection of neoplastic cells in lymph nodes of metastatic colorectal cancer patients predicts recurrence. Clin Cancer Res 5:2450–2454 Sanchez-Cespedes M, Esteller M, Hibi K, Cope FO, Westra WH, Piantadosi S, Herman JG, Jen J, Sidransky D (1999) Molecular detection of neoplastic cells in lymph nodes of metastatic colorectal cancer patients predicts recurrence. Clin Cancer Res 5:2450–2454
6.
Zurück zum Zitat Greenson JK, Isenhart CE, Rice R, Mojzisik C, Houchens D, Martin EW (1994) Identification of occult micrometastases in pericolic lymph nodes of Duke’s B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with long-term survival. Cancer 73:563–569PubMed Greenson JK, Isenhart CE, Rice R, Mojzisik C, Houchens D, Martin EW (1994) Identification of occult micrometastases in pericolic lymph nodes of Duke’s B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with long-term survival. Cancer 73:563–569PubMed
7.
Zurück zum Zitat Miyake Y, Yamamoto H, Fujiwara Y, Ohue M, Sugita Y, Tomita N, Sekimoto M, Matsuura N, Shiozaki H, Monden M (2001) Extensive micrometastases to lymph nodes as a marker for rapid recurrence of colorectal cancer: a study of lymphatic mapping. Clin Cancer Res 7:1350–1357 Miyake Y, Yamamoto H, Fujiwara Y, Ohue M, Sugita Y, Tomita N, Sekimoto M, Matsuura N, Shiozaki H, Monden M (2001) Extensive micrometastases to lymph nodes as a marker for rapid recurrence of colorectal cancer: a study of lymphatic mapping. Clin Cancer Res 7:1350–1357
8.
Zurück zum Zitat Vogel I, Kalthoff H (2001) Disseminated tumour cells. Their detection and significance for prognosis of gastrointestinal and pancreatic carcinomas. Virchows Arch 439:109–117CrossRefPubMed Vogel I, Kalthoff H (2001) Disseminated tumour cells. Their detection and significance for prognosis of gastrointestinal and pancreatic carcinomas. Virchows Arch 439:109–117CrossRefPubMed
9.
Zurück zum Zitat Weitz J, Kienle P, Magener A, Koch M, Schrodel A, Willeke F, Autschbach F, Lacroix J, Lehnert T, Herfarth C, von Knebel-Doeberitz M (1999) Detection of disseminated colorectal cancer cells in lymph nodes, blood and bone marrow. Clin Cancer Res 5:1830–1836 Weitz J, Kienle P, Magener A, Koch M, Schrodel A, Willeke F, Autschbach F, Lacroix J, Lehnert T, Herfarth C, von Knebel-Doeberitz M (1999) Detection of disseminated colorectal cancer cells in lymph nodes, blood and bone marrow. Clin Cancer Res 5:1830–1836
10.
Zurück zum Zitat O’Sullivan GC, Collins JK, Kelly J, Morgan J, Madden M, Shanahan F (1997) Micrometastases: marker of metastatic potential or evidence of residual disease? Gut 40:512–515PubMed O’Sullivan GC, Collins JK, Kelly J, Morgan J, Madden M, Shanahan F (1997) Micrometastases: marker of metastatic potential or evidence of residual disease? Gut 40:512–515PubMed
11.
Zurück zum Zitat Soeth E, Roder C, Juhl H, Kruger U, Kremer B, Kalthoff H (1996) The detection of disseminated tumor cells in bone marrow from colorectal-cancer patients by a cytokeratin-20-specific nested reverse-transcriptase-polymerase-chain reaction is related to the stage of disease. Int J Cancer 69:278–282CrossRefPubMed Soeth E, Roder C, Juhl H, Kruger U, Kremer B, Kalthoff H (1996) The detection of disseminated tumor cells in bone marrow from colorectal-cancer patients by a cytokeratin-20-specific nested reverse-transcriptase-polymerase-chain reaction is related to the stage of disease. Int J Cancer 69:278–282CrossRefPubMed
12.
Zurück zum Zitat Leinung S, Wurl P, Weiss CL, Roder I, Schonfelder M (2000) Cytokeratin-positive cells in bone marrow in comparison with other prognostic factors in colon carcinoma. Langenbecks Arch Surg 385:337–343CrossRefPubMed Leinung S, Wurl P, Weiss CL, Roder I, Schonfelder M (2000) Cytokeratin-positive cells in bone marrow in comparison with other prognostic factors in colon carcinoma. Langenbecks Arch Surg 385:337–343CrossRefPubMed
13.
Zurück zum Zitat Leinung S, Wurl P, Schonfelder A, Weiss CL, Roder I, Schonfelder M (2000) Detection of cytokeratin-positive cells in bone marrow in breast cancer and colorectal carcinoma in comparison with other factors of prognosis. J Hematother Stem Cell Res 9:905–911CrossRefPubMed Leinung S, Wurl P, Schonfelder A, Weiss CL, Roder I, Schonfelder M (2000) Detection of cytokeratin-positive cells in bone marrow in breast cancer and colorectal carcinoma in comparison with other factors of prognosis. J Hematother Stem Cell Res 9:905–911CrossRefPubMed
14.
Zurück zum Zitat Hardingham JE, Kotasek D, Sage RE, Eaton MC, Pascoe VH, Dobrovic A (1995) Detection of circulating tumor cells in colorectal cancer by immunobead-PCR is a sensitive prognostic marker for relapse of disease. Mol Med 1:789–794PubMed Hardingham JE, Kotasek D, Sage RE, Eaton MC, Pascoe VH, Dobrovic A (1995) Detection of circulating tumor cells in colorectal cancer by immunobead-PCR is a sensitive prognostic marker for relapse of disease. Mol Med 1:789–794PubMed
15.
Zurück zum Zitat Hardingham JE, Hewett PJ, Sage RE, Finch JL, Nuttall JD, Kotasek D, Dobrovic A (2000) Molecular detection of blood-borne epithelial cells in colorectal cancer patients and in patients with benign bowel disease. Int J Cancer 89:8–13CrossRefPubMed Hardingham JE, Hewett PJ, Sage RE, Finch JL, Nuttall JD, Kotasek D, Dobrovic A (2000) Molecular detection of blood-borne epithelial cells in colorectal cancer patients and in patients with benign bowel disease. Int J Cancer 89:8–13CrossRefPubMed
16.
Zurück zum Zitat Taniguchi T, Makino M, Suzuki K, Kaibara N (2000) Prognostic significance of reverse transcriptase-polymerase chain reaction measurement of carcinoembryonic antigen mRNA levels in tumor drainage blood and peripheral blood of patients with colorectal carcinoma. Cancer 89:970–976CrossRefPubMed Taniguchi T, Makino M, Suzuki K, Kaibara N (2000) Prognostic significance of reverse transcriptase-polymerase chain reaction measurement of carcinoembryonic antigen mRNA levels in tumor drainage blood and peripheral blood of patients with colorectal carcinoma. Cancer 89:970–976CrossRefPubMed
17.
Zurück zum Zitat Soeth E, Vogel I, Roder C, Juhl H, Marxsen J, Kruger U, Henne-Bruns D, Kremer B, Kalthoff H (1997) Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR Cancer Res 57:3106–3110 Soeth E, Vogel I, Roder C, Juhl H, Marxsen J, Kruger U, Henne-Bruns D, Kremer B, Kalthoff H (1997) Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR Cancer Res 57:3106–3110
18.
Zurück zum Zitat Schimanski CC, Sutter C, Linnemann U, Berger MR (1999) Sampling technique influences the detection of K-ras mutations in normal appearing mucosa of colorectal cancer patients. Int J Oncol 15:391–398PubMed Schimanski CC, Sutter C, Linnemann U, Berger MR (1999) Sampling technique influences the detection of K-ras mutations in normal appearing mucosa of colorectal cancer patients. Int J Oncol 15:391–398PubMed
19.
Zurück zum Zitat Schimanski CC, Linnemann U, Arbogast R, Berger MR (2001) Extended staging results from the detection of isolated tumor cells in the liver of colorectal cancer patients. Oncol Rep 8:185–188PubMed Schimanski CC, Linnemann U, Arbogast R, Berger MR (2001) Extended staging results from the detection of isolated tumor cells in the liver of colorectal cancer patients. Oncol Rep 8:185–188PubMed
20.
Zurück zum Zitat Schimanski CC, Linnemann U, Berger MR (1999) Sensitive detection of K-ras mutations augments diagnosis of colorectal cancer metastases in the liver. Cancer Res 59:5169–5175PubMed Schimanski CC, Linnemann U, Berger MR (1999) Sensitive detection of K-ras mutations augments diagnosis of colorectal cancer metastases in the liver. Cancer Res 59:5169–5175PubMed
21.
Zurück zum Zitat Kalbfleisch LD, Prentice RL (eds) (1980) The statistical analysis of failure time data. Wiley, New York Kalbfleisch LD, Prentice RL (eds) (1980) The statistical analysis of failure time data. Wiley, New York
22.
Zurück zum Zitat Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA (1998) Kirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” study. J Natl Cancer Inst 90:675–684CrossRefPubMed Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA (1998) Kirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” study. J Natl Cancer Inst 90:675–684CrossRefPubMed
23.
Zurück zum Zitat Andreyev H, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M et al (2001) Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Cancer 85:692–696CrossRefPubMed Andreyev H, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M et al (2001) Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Cancer 85:692–696CrossRefPubMed
24.
Zurück zum Zitat Schimanski CC, Linnemann U, Galle PR, Arbogast R, Berger MR (2003) Hepatic disseminated tumor cells in colorectal cancer UICC stage 4 patients: Prognostic implications. Int J Oncol 23:791–796PubMed Schimanski CC, Linnemann U, Galle PR, Arbogast R, Berger MR (2003) Hepatic disseminated tumor cells in colorectal cancer UICC stage 4 patients: Prognostic implications. Int J Oncol 23:791–796PubMed
25.
Zurück zum Zitat Weitz J, Kienle P, Lacroix J, Willeke F, Benner A, Lehnert T, Herfarth C, von Knebel-Doeberitz M (1998) Dissemination of tumor cells in patients undergoing surgery for colorectal cancer. Clin Cancer Res 4:343–348PubMed Weitz J, Kienle P, Lacroix J, Willeke F, Benner A, Lehnert T, Herfarth C, von Knebel-Doeberitz M (1998) Dissemination of tumor cells in patients undergoing surgery for colorectal cancer. Clin Cancer Res 4:343–348PubMed
26.
Zurück zum Zitat Weitz J, Koch M, Kienle P, Schrodel A, Willeke F, Benner A, Lehnert T, Herfarth C, von Knebel-Doeberitz M (2000) Detection of hematogenic tumor cell dissemination in patients undergoing resection of liver metastases of colorectal cancer. Ann Surg 232:66–72PubMed Weitz J, Koch M, Kienle P, Schrodel A, Willeke F, Benner A, Lehnert T, Herfarth C, von Knebel-Doeberitz M (2000) Detection of hematogenic tumor cell dissemination in patients undergoing resection of liver metastases of colorectal cancer. Ann Surg 232:66–72PubMed
27.
Zurück zum Zitat Wharton RQ, Jonas SK, Glover C, Khan ZA, Klokouzas A, Quinn H, Henry M, Allen Mersh TG (1999) Increased detection of circulating tumor cells in the blood of colorectal carcinoma patients using two reverse transcription-PCR assays and multiple blood samples. Clin Cancer Res 5:4158–4163 Wharton RQ, Jonas SK, Glover C, Khan ZA, Klokouzas A, Quinn H, Henry M, Allen Mersh TG (1999) Increased detection of circulating tumor cells in the blood of colorectal carcinoma patients using two reverse transcription-PCR assays and multiple blood samples. Clin Cancer Res 5:4158–4163
28.
Zurück zum Zitat Schirmacher P, Dienes HP, Moll R (1998) De novo expression of nonhepatocellular cytokeratins in Mallory body formation. Virchows Arch 432:143–152CrossRefPubMed Schirmacher P, Dienes HP, Moll R (1998) De novo expression of nonhepatocellular cytokeratins in Mallory body formation. Virchows Arch 432:143–152CrossRefPubMed
29.
Zurück zum Zitat Weiss L (1996) Metastatic inefficiency: intravascular and intraperitoneal implantation of cancer cells. Cancer Treat Res 82:1–11PubMed Weiss L (1996) Metastatic inefficiency: intravascular and intraperitoneal implantation of cancer cells. Cancer Treat Res 82:1–11PubMed
30.
Zurück zum Zitat Riethmüller G, Schneider Gadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R et al (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 343:1177–1183PubMed Riethmüller G, Schneider Gadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R et al (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet 343:1177–1183PubMed
31.
Zurück zum Zitat Riethmüller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Funke I, Pichlmaier H, Hirche H, Buggisch P, Witte J, Pichlmayr R (1998) Monoclonal antibody therapy for resected Dukes’ C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 16:1788–1794PubMed Riethmüller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Funke I, Pichlmaier H, Hirche H, Buggisch P, Witte J, Pichlmayr R (1998) Monoclonal antibody therapy for resected Dukes’ C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 16:1788–1794PubMed
32.
Zurück zum Zitat Juweid ME, Stadtmauer E, Hajjar G, Sharkey RM, Suleiman S, Luger S, Swayne LC, Alavi A, Goldenberg DM (1999) Pharmacokinetics, dosimetry, and initial therapeutic results with131I- and (111) In-90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin’s lymphoma. Clin Cancer Res 5 [Suppl]:3292s–3303s Juweid ME, Stadtmauer E, Hajjar G, Sharkey RM, Suleiman S, Luger S, Swayne LC, Alavi A, Goldenberg DM (1999) Pharmacokinetics, dosimetry, and initial therapeutic results with131I- and (111) In-90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin’s lymphoma. Clin Cancer Res 5 [Suppl]:3292s–3303s
Metadaten
Titel
Prognostic value of disseminated colorectal tumor cells in the liver: results of follow-up examinations
verfasst von
Ulrich Linnemann
Christoph C. Schimanski
Christoph Gebhardt
Martin R. Berger
Publikationsdatum
01.07.2004
Verlag
Springer-Verlag
Erschienen in
International Journal of Colorectal Disease / Ausgabe 4/2004
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-003-0555-3

Weitere Artikel der Ausgabe 4/2004

International Journal of Colorectal Disease 4/2004 Zur Ausgabe

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Recycling im OP – möglich, aber teuer

05.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO2-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Im OP der Zukunft läuft nichts mehr ohne Kollege Roboter

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Nur selten Nachblutungen nach Abszesstonsillektomie

03.05.2024 Tonsillektomie Nachrichten

In einer Metaanalyse von 18 Studien war die Rate von Nachblutungen nach einer Abszesstonsillektomie mit weniger als 7% recht niedrig. Nur rund 2% der Behandelten mussten nachoperiert werden. Die Therapie scheint damit recht sicher zu sein.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.